HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

meso-chlorin e(6) monoethylene diamine

RN given for (2S-trans)-isomer; structure in first source
Also Known As:
Mce(6); Mce(6) disodium salt; Mce6 cpd; meso-chlorin e(6) monoethylene diamine, disodium salt; meso-chlorin e6 monoethylenediamine; mesochlorin e6 monoethylenediamine
Networked: 9 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Kopecek, J: 4 articles (03/2008 - 03/2000)
2. Kopecková, P: 3 articles (03/2008 - 11/2000)
3. Kopecková, Pavla: 2 articles (09/2008 - 06/2003)
4. Peterson, C M: 2 articles (07/2001 - 03/2000)
5. Shiah, J G: 2 articles (07/2001 - 03/2000)
6. Straight, R C: 2 articles (07/2001 - 03/2000)
7. Sun, Y: 2 articles (07/2001 - 03/2000)
8. Borges, Gilberto Antonio: 1 article (12/2013)
9. Burnett Júnior, Luiz Henrique: 1 article (12/2013)
10. Mota, Eduardo Gonçalves: 1 article (12/2013)

Related Diseases

1. Carcinoma (Carcinomatosis)
11/01/2000 - "The acquisition of multidrug resistance in human ovarian carcinoma A2780 cells was investigated after chronic exposure to free mesochlorin e6 monoethylenediamine (Mce6) and N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound Mce6 (P(GG)-Mce6). "
06/01/2003 - "Here, we investigated mechanisms of toxicity in human ovarian carcinoma A2780 cells treated with structurally diverse N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer (P)-mesochlorin e6 monoethylenediamine (Mce6) conjugates that possessed differential subcellular accumulation or covalent attachments of photosensitizers (or both). "
08/27/1999 - "The purpose of this study was to examine the biodistribution of the photosensitizing drug, mesochlorin e(6) monoethylenediamine (Mce(6)), and the antineoplastic agent, adriamycin (ADR), as well as their N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates in female nu/nu athymic mice bearing human ovarian carcinoma OVCAR-3 xenografts. "
09/01/2008 - "The biological activities of sequential combinations of anticancer drugs, SOS thiophene (SOS) and mesochlorin e 6 monoethylenediamine (Mce 6), in the form of free drugs, nontargeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates, P-GFLG-Mce 6 and P-GFLG-SOS (P is the HPMA copolymer backbone and GFLG is the glycylphenylalanylleucylglycine spacer), and Fab'-targeted HPMA copolymer-drug conjugates, P-(GFLG-Mce 6)-Fab' and P-(GFLG-SOS)-Fab' (Fab' from OV-TL16 antibodies complementary to CD47), were evaluated against human ovarian carcinoma OVCAR-3 cells. "
07/06/2001 - "The aim of this study was to evaluate the combination chemotherapy and photodynamic therapy of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound doxorubicin (DOX) and mesochlorin e(6) (Mce(6)) targeted with an OV-TL 16 monoclonal antibody (P-DOX-Ab and P-Mce(6)-Ab, respectively) in nude mice bearing human ovarian OVCAR-3 carcinoma xenografts. "
2. Neoplasms (Cancer)
3. Renal Cell Carcinoma (Grawitz Tumor)
4. AIDS-Related Complex (ARC)

Related Drugs and Biologics

1. N-(2-hydroxypropyl)methacrylamide
2. hydroxypropyl methacrylate
3. Doxorubicin (Adriamycin)
4. 1-phenyl-3,3-dimethyltriazene (PDT)
5. Monoclonal Antibodies
6. Antineoplastic Agents (Antineoplastics)
7. Thiophenes
8. Member 1 Subfamily B ATP Binding Cassette Transporter
9. Photosensitizing Agents (Photosensitizers)
10. Antibodies

Related Therapies and Procedures

1. Photochemotherapy (Photodynamic Therapy)
2. Drug Therapy (Chemotherapy)
3. Combination Drug Therapy (Combination Chemotherapy)
4. Inlays (Inlay)